Table 3.

Changes in Gene Expression in Isolated Microvesses From Subjects With CAD vs. Non-CAD Diagniosis

		Atrial			Adipose			Total
		Both Genders	Male	Female	Both Genders	Male	Female	Both Genders	Male	Female
PGC1α	Non-CAD	1.00 ± 0.79	1.00 ± 0.71	1.00 ± 0.94	1.00 ± 0.38	1.00 ± 0.37	1.00 ± 0.44	1.00 ± 0.70	1.00 ± 0.65	1.00 ± 0.81
	CAD	0.66 ± 0.62	1.52 ± 1.03	0.26 ± 0.25$	0.89 ± 0.36	0.62 ± 0.28	0.98&	0.73 ± 0.57	1.05 ± 0.58	0.35 ± 0.33
CAT	Non-CAD	1.00 ± 0.36	1.00 ± 0.24	1.00 ± 0.54	1.00 ± 0.43	1.00 ± 0.31	1.00 ± 0.52	1.00 ± 0.39	1.00 ± 0.26	1.00 ± 0.53
	CAD	0.97 ± 0.42	1.03 ± 0.35	0.80 ± 0.35	0.97 ± 0.38	1.28 ± 0.46	0.70&	0.97 ± 0.41	1.07 ± 0.40	0.78 ± 0.32
SOD2	Non-CAD	1.00 ± 0.53	1.00 ± 0.59	1.00 ± 0.64	1.00 ± 0.48	1.00 ± 0.06	1.00 ± 0.50	1.00 ± 0.51	1.00 ± 0.52	1.00 ± 0.59
	CAD	0.61 ± 0.55*	1.49 ± 1.75	0.43 ± 0.27*	0.77 ± 0.38*	0.44 ± 0.29*	0.94&	0.66 ± 0.51*	0.75 ± 0.59	0.50 ± 0.31*
PARP1	Non-CAD	1.00 ± 0.37	1.00 ± 0.16	1.00 ± 0.56	1.00 ± 0.57	1.00 ± 0.38	1.00 ± 0.74	1.00 ± 0.45	1.00 ± 0.24	1.00 ± 0.64
	CAD	0.85 ± 0.31	0.97 ± 0.33	0.73 ± 0.38	0.90 ± 0.29	0.99 ± 0.35	0.75&	0.86 ± 0.30	0.98 ± 0.34	0.73 ± 0.36
OGG1	Non-CAD	1.00 ± 0.61	1.00 ± 0.59	1.00 ± 0.67	1.00 ± 0.37	1.00 ± 0.22	1.00 ± 0.14	1.00 ± 0.54	1.00 ± 0.52	1.00 ± 0.55
	CAD	0.79 ± 0.33	1.23 ± 1.07	0.87 ± 0.45	0.87 ± 0.47	0.62 ± 0.43	0.90&	0.78 ± 0.41	1.02 ± 0.95	0.87 ± 0.42
SIRT3	Non-CAD	1.00 ± 0.51	1.00 ± 0.32	1.00 ± 0.46	1.00 ± 0.54	1.00 ± 0.24	1.00 ± 0.70	1.00 ± 0.52	1.00 ± 0.31	1.00 ± 0.57
	CAD	0.87 ± 0.46	1.00 ± 0.45	0.73 ± 0.29	1.11 ± 0.62	1.17 ± 0.64	0.87&	0.95 ± 0.53	1.04 ± 0.54	0.75 ± 0.27

Data presented as fold change to non-CAD mean ± SD; N = 4–17.

^& N = 1 (not statistical evaluation possible) * P < 0.05 unpaired t-test; ^$P < 0.1 unpaired t-test.